Evidence map›Paper›PMID 39063006›Full record

ArticleInternational journal of molecular sciences2024

Di- and Triselenoesters-Promising Drug Candidates for the Future Therapy of Triple-Negative Breast Cancer.

Dominika Radomska, Robert Czarnomysy, Anna Szymanowska, Dominik Radomski, Magda Chalecka, Arkadiusz Surazynski, Enrique Domínguez-Álvarez, Anna Bielawska, Krzysztof Bielawski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dominika RadomskaDepartment of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland.ORCID 0000-0002-4747-0312
Robert CzarnomysyDepartment of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland.ORCID 0000-0002-7148-6111
Anna SzymanowskaDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0003-4783-3336
Dominik RadomskiDepartment of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland.
Magda ChaleckaDepartment of Medicinal Chemistry, Medical University of Bialystok, Mickiewicza 2D, 15-222 Bialystok, Poland.
Arkadiusz SurazynskiDepartment of Medicinal Chemistry, Medical University of Bialystok, Mickiewicza 2D, 15-222 Bialystok, Poland.ORCID 0000-0003-4475-873X
Enrique Domínguez-ÁlvarezInstituto de Química Orgánica General (IQOG-CSIC), Consejo Superior de Investigaciones Científicas, Juan de la Cierva 3, 28006 Madrid, Spain.ORCID 0000-0003-2655-1575
Anna BielawskaDepartment of Biotechnology, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland.
Krzysztof BielawskiDepartment of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland.ORCID 0000-0003-3187-4205

Funding

Medical University of Białystok B.SUB.23.162
6 · The paper itself

Abstract

Breast cancer is a major malignancy among women, characterized by a high mortality rate. The available literature evidence indicates that selenium, as a trace element, has chemopreventive properties against many types of cancer; as such, compounds containing it in their structure may potentially exhibit anticancer activity. Accordingly, we have undertaken a study to evaluate the effects of novel selenoesters (EDAG-1, -7, -8, -10) on MCF-7 and MDA-MB-231 breast cancer cells. Our analysis included investigations of cell proliferation and viability as well as cytometric determinations of apoptosis/autophagy induction, changes in mitochondrial membrane polarity (ΔΨ

Indexed as

Antineoplastic AgentsApoptosisAutophagyCell ProliferationTriple Negative Breast NeoplasmsCell Line, TumorCell SurvivalEstersFemaleHumansMCF-7 CellsMembrane Potential, MitochondrialOrganoselenium CompoundsAntineoplastic AgentsEstersOrganoselenium Compoundsanticancer drugsapoptosisautophagybreast cancercancer treatmentorganoselenium compoundsselenium compoundsselenoesterssignaling pathwaystriple-negative breast cancer

Identifiers

PMID39063006
PMCPMC11277004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.